Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh - LARVOL DELTA

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Olivera Finn | Trial completion date: Oct 2031 ➔ Oct 2032 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Colonic Polyps • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Oncology • Solid Tumor

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Lung Cancer • Oncology • Solid Tumor • CRP • IL6 • MUC1

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Olivera Finn | Trial completion date: Sep 2029 ➔ Oct 2031 | Trial primary completion date: Jul 2024 ➔ Oct 2026

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: National Cancer Institute (NCI)

Metastases • Trial completion date • Colonic Polyps • Colorectal Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Lung Cancer • Oncology • Solid Tumor • CRP • IL6 • MUC1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Lung Cancer • Oncology • Solid Tumor

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2022 ➔ Jun 2023

Trial completion date • Lung Cancer • Oncology • Solid Tumor

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Olivera Finn | Trial completion date: Sep 2022 ➔ Sep 2029 | Trial primary completion date: Jul 2022 ➔ Jul 2024

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Dec 2021 ➔ Dec 2022

Clinical • Trial completion date • Lung Cancer • Oncology • Solid Tumor

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Lung Cancer • Oncology • Solid Tumor

[VIRTUAL] THE REVERSAL OF IMMUNE EXCLUSION MEDIATED BY TADALAFIL AND AN ANTI-TUMOR VACCINE ALSO INDUCES PDL1 UP REGULATION IN RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA: FINAL ANALYSIS INCLUDING CLINICAL OUTCOMES OF A PHASE I CLINICAL TRIAL (AHNS 2021) - P1/2 | "The combined treatment of Tadalafil and MUC1/polyICLC vaccine was well tolerated with no serious adverse events or treatment limiting toxicities. All patients were previously irradiated as per study protocol, with 5 of 7 on the active treatment arm and 5 of 6 on the control arm receiving chemotherapy with radiation therapy as part of their prior treatment. Long term (two years) clinical outcomes and toxicity data of 7 evaluable treatment patients and 6 control patients will be reported in addition to long term analyses of the immunomodulatory effects of the treatment intervention."

Clinical • Clinical data • P1 data • Head and Neck Cancer • Immune Modulation • Immunology • Inflammation • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD163 • CD8 • MUC1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Dec 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Solid Tumor

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: National Cancer Institute (NCI); Suspended ➔ Recruiting

Clinical • Enrollment open • Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • CA 15-3 • MUC1

MUC1 Vaccine for Triple-negative Breast Cancer (clinicaltrials.gov) - P1; N=29; Completed; Sponsor: Joseph Baar, MD, PhD; Active, not recruiting ➔ Completed

Trial completion • Biosimilar • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Suspended; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Suspended

Clinical • Trial suspension • MUC1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jul 2021 ➔ Dec 2020; Trial primary completion date: Jul 2021 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • MUC1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Dec 2019 ➔ Jul 2021; Trial primary completion date: Dec 2019 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • MUC1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Not yet recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • New P1 trial

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma (clinicaltrials.gov) - P2; N=46; Completed; Sponsor: University of Pittsburgh; N=65 ➔ 46

Clinical • Enrollment change

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jul 2019 ➔ Dec 2019; Trial primary completion date: Jul 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma (clinicaltrials.gov) - P2; N=46; Completed; Sponsor: University of Pittsburgh; Recruiting ➔ Completed

Clinical • Trial completion

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: National Cancer Institute (NCI); Not yet recruiting ➔ Recruiting

Clinical • Enrollment open